https://telixpharma.com/news-media/eau-2022-wrap-up-how-are-psma-diagnostics-changing-the-landscape-for-prostate-cancer-care/
EAU 2022 wrap-up: How are PSMA diagnostics changing the landscape for prostate cancer care?
At the recent EAU 2022 symposium, Telix brought together prostate cancer management specialists to discuss all aspects of PSMA PET imaging. It was an exciting journey, filled with fascinating insights. If you missed the event, or if you want to revisit a stop or two, you can find the key takeaways from each of our expert travelers below. The train is moving fast – so take a moment to listen to the highlights and ensure your PSMA knowledge is right on track.
Prof Stefano Fanti: What is PSMA all about?
- PSMA PET/CT is now recognised as the most sensitive and specific imaging approach in prostate cancer.
- Not all PSMA tracers are the same. You have to know the differences and choose wisely.
- PSMA PET/CT is becoming more prevalent in EAU, growing to an extent that experts in nuclear medicine would never have expected.
- Collaboration is key – together, urologists, clinicians and oncologists can truly make a difference to patient outcomes.
Prof Jochen Waltz: When does PSMA help me?
- The 3 areas of clinical use for PSMA PET/CT imaging in prostate cancer management:Initial staging – Compared to conventional techniques, initial staging with PSMA is a more reliable and sensitive imaging tool
- PSA persistence after surgery – PSMA PET/CT helps us to clearly understand PSA persistance after surgery, helping patients who are most prone to prostate cancer progression.
- Biochemical Recurrence – Understanding where prostate cancer has spread to other parts of the body is important for choosing optimal treatment approach.
Dr Alicia Morgans: The future of prostate cancer management
- When we see things more clearly, we can treat patients more effectively: PSMA PET/CT allows us to identify lesions at any stage.
- PSMA PET/CT is a game-changing theranostic that helps us to find more effective ways to treat patients and prolong life.
- Get on board the PSMA train! We have an exciting journey ahead.
https://virtual.uroweb.org/resource-centre/EAU22?session_id=12984#showhttps://virtual.uroweb.org/resource-centre/EAU22/240103/Webcast/
https://virtual.uroweb.org/resource-centre/EAU22/240112/Webcast/
https://virtual.uroweb.org/resource-centre/EAU22/240118/Webcast/
https://virtual.uroweb.org/resource-centre/EAU22/240124/Webcast/
https://virtual.uroweb.org/resource-centre/EAU22/241438/On%20demand%20session/
- Forums
- ASX - By Stock
- TLX
- Telix at the European Association of Urology Congress 2022, Focus on PSMA-PET Imaging
Telix at the European Association of Urology Congress 2022, Focus on PSMA-PET Imaging, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$19.19 |
Change
0.780(4.24%) |
Mkt cap ! $6.421B |
Open | High | Low | Value | Volume |
$18.85 | $19.19 | $18.78 | $22.02M | 1.155M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2216 | $19.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.20 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1 | 19.090 |
1 | 10000 | 19.050 |
2 | 10000 | 19.040 |
2 | 1100 | 19.000 |
1 | 1000 | 18.930 |
Price($) | Vol. | No. |
---|---|---|
19.200 | 1000 | 1 |
19.250 | 5000 | 1 |
19.290 | 5000 | 1 |
19.300 | 2172 | 2 |
19.390 | 5000 | 1 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |